Laurence Blumberg, M.D., has a long career as a biopharmaceutical entrepreneur, operating executive and analyst. He co-founded Syntimmune with Richard Blumberg, M.D., in 2013, and served as chief executive officer of the firm until November 2015. Prior to Syntimmune, he was senior vice president, project management at Kadmon, leading new product development activities. Before joining Kadmon, he was co-founder and member of the board of Syntonix Pharmaceuticals (sold to Biogen Idec in 2007). Earlier, he was senior global biotechnology analyst for Alliance Capital and co-founder of Cambridge Heart, a medical diagnostics firm. Dr. Blumberg received his MBA from Columbia Business School, where he serves as entrepreneur in residence.